Skip to content
  • Research
  • Desk Notes

Recent Desk Notes

SNT – 1st Cohort of AZALOX Trial Complete, Preliminary Data Expected Q4 CY26

SNT – 1st Cohort of AZALOX Trial Complete, Preliminary Data Expected Q4 CY26

21 Jul 2026
OSL – Delivers on Milestones as Stock Re-Rates, Catalysts Still Ahead

OSL – Delivers on Milestones as Stock Re-Rates, Catalysts Still Ahead

14 Jul 2026
Entropy Logo

ENP – Entropy Reports Cohort 1 Topline Results in Treatment-Resistant Binge Eating Disorder

10 Jul 2026
ILA – Galidesivir Cleared for Compassionate Use in the Bundibugyo Ebola Outbreak

ILA – Galidesivir Cleared for Compassionate Use in the Bundibugyo Ebola Outbreak

7 Jul 2026
OSL – Regulatory Progress Supports a Catalyst-Rich 2H CY2026

OSL – Regulatory Progress Supports a Catalyst-Rich 2H CY2026

3 Jul 2026

© 2026 Prenzler Group - All Rights Reserved. 

Prenzler Group Pty Ltd (ABN 77 621 100 730) is a corporate Authorised Representative (1257636) of BR Securities Australia Pty Ltd (ABN 92 168 734 530), the holder of Australian Financial Services Licence number 456663. The information contained in this website is only intended for the use of those persons who satisfy the Wholesale definition, pursuant to Section 761G and Section 761GA of the Corporations Act 2001 (Cth) (“the Act”). Persons accessing this information should consider whether they are wholesale clients in accordance with the Act before relying on any information contained. Any advice provided is general in nature.

Prenzler Group FSG

Privacy Policy

Disclaimers

  • Research
  • Desk Notes